Nucleus Software Exports Limited has announced the appointment of Dr. Apurva Chamaria as Chief Business Officer effective February 02, 2026. The company disclosed this strategic appointment through a press release to stock exchanges under Regulation 30 of the Securities and Exchange Board of India regulations.

Appointment Details

The appointment details are outlined in the company's regulatory filing:

Strategic Leadership Addition

Commenting on the appointment, Parag Bhise, CEO & Executive Director of Nucleus Software, emphasized the strategic importance of this hire: "As we continue to scale our operations and expand our global footprint, getting an impactful leaders to be part of this journey is paramount. Dr. Apurva brings exceptional strategic thinking, deep industry knowledge, and a customer-first approach that will be invaluable as we pursue our next phase of growth."

Dr. Apurva Chamaria expressed his enthusiasm about joining the company: "I am excited to join Nucleus Software at this pivotal moment in the company's journey. The opportunity to work with a talented team, industry-leading solutions, and a diverse global client base is truly compelling. I look forward to contributing to Nucleus Software's growth trajectory and helping our customers navigate their business challenges in an AI first world with confidence and success."

Professional Background and Experience

Dr. Apurva Chamaria brings extensive leadership experience spanning over 23 years across diverse functions including sales, marketing, partnerships, business development, and mergers & acquisitions. His career trajectory includes senior roles at several respected organizations in India's corporate landscape.

Career Highlights

Dr. Chamaria's professional journey encompasses leadership positions at:

• Google: Most recently served as Global Head of Startups, VC & Private Equity Partnerships
• RateGain: Previously held the position of Chief Revenue Officer, where he achieved significant revenue growth
• Tech Mahindra: Contributed to the company's business development initiatives
• HCL Technologies: Gained experience in technology sector operations
• Ranbaxy: Early career experience in pharmaceutical industry

Educational Qualifications and Recognition

Dr. Chamaria's academic credentials reflect a comprehensive educational background from premier institutions. He is an alumnus of Mayo College, IIT Delhi, IIMC, IMI and Harvard Business School. His international exposure includes professional experience across multiple countries including the United States, United Kingdom, South Africa, Australia and India.

Industry Recognition

His contributions to the industry have earned him several notable recognitions:

• Named Campaign Asia 40 under 40
• Honored as Fellow of the All-India Management Association (AIMA) in 2020
• Member of Young Presidents Organization (YPO)
• Author of two bestselling books published by Bloomsbury and Penguin Random House

Strategic Impact and Growth Focus

The appointment comes at a time when Nucleus Software is experiencing strong momentum in cloud-native lending solutions, transaction banking platforms, and AI-driven innovations for the BFSI sector. Dr. Chamaria will be responsible for driving business growth, deepening customer relationships, and advancing the company's expansion strategy across key markets.

This strategic appointment reinforces Nucleus Software's commitment to strengthening its leadership and scaling its business operations globally. His leadership will be instrumental in accelerating go-to-market strategies, strengthening partnerships, and expanding customer engagement across geographies.

Nucleus Software Exports Limited has announced a board meeting scheduled for February 10, 2026, to approve the company's financial results for the third quarter of fiscal year 2026. The meeting notification was issued on January 21, 2026, in compliance with regulatory requirements.

Board Meeting Agenda

The board meeting has been convened to address two primary objectives for the quarter and nine months ending December 31, 2025:

The company has specified that both sets of financial results cover the same reporting period, providing comprehensive insights into the company's performance across standalone and consolidated operations.

Regulatory Compliance

The announcement was made under Regulation 29(2) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has formally notified both major stock exchanges where its shares are listed:

Company Secretary Poonam Bhasin signed the official notice, which was digitally authenticated on January 21, 2026, at 17:04:30 +05'30'.

Timeline and Declaration

The financial results, once duly approved by the Board of Directors, will be declared immediately at the conclusion of the board meeting on February 10, 2026. This timeline ensures prompt disclosure of the company's Q3FY26 performance to stakeholders and the investment community.

The company's registered office is located at 33-35 Thyagraj Nagar, New Delhi - 110003, from where the official communication was issued to maintain transparency and regulatory compliance.